secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001437749-25-004126
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Genprex signs amended exclusive license with Univ of Pittsburgh for diabetes gene therapy, forms subsidiary
--------------------------------------------------------------------------------

- Entered amended and restated exclusive license with Univ of Pittsburgh for T1D and T2D gene therapy using Pdx1 and MafA genes.
- License includes milestone payments up to approximately $4,825,000 and low single-digit royalties on sales.
- Terminated prior license agreements, including the November 2022 macrophage technology license.
- Formed wholly-owned subsidiary Convergen Biotech, Inc. to focus on diabetes program development.
- Plans to request FDA guidance for IND-enabling diabetes studies by the second half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925004126/0001437749-25-004126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925004126/gnpx20241220c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-004126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer